Commercial Real Estate Company K.P.S.C. (KWSE:ALTIJARIA)

Ligand Pharmaceuticals Income Statement

Financials in millions KWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	31.64	31.32	30.6	29.63	43.25	20.52
Other Revenue	-1.06	-	-	-	-	-0.61
Revenue	30.58	31.32	30.6	29.63	43.25	19.91
Revenue Growth (YoY)	-12.35%	2.32%	3.30%	-31.51%	117.28%	-46.74%
Cost of Revenue	10.33	9.99	8.52	7.9	8.55	7.15
Gross Profit	20.25	21.33	22.09	21.73	34.71	12.76
Selling, General & Admin	3.1	3.08	3.04	2.12	2.66	2.6
Other Operating Expenses	-0.18	-0.15	0.22	0.21	0.27	0.85
Operating Expenses	2.51	2.93	3.26	2.33	2.93	3.45
Operating Income	17.74	18.4	18.83	19.39	31.78	9.3
Interest Expense	-12.13	-12.49	-11.26	-6.66	-5.5	-6.43
Earnings From Equity Investments	5.24	5.24	2.71	-2.23	-0.63	-
Other Non Operating Income (Expenses)	-1.44	-1.45	-2.37	-1.57	-2.36	-
EBT Excluding Unusual Items	9.41	9.69	7.91	8.93	23.28	2.88
Gain (Loss) on Sale of Investments	8.37	8.37	10.11	8.04	-1.74	-
Asset Writedown	-0.52	-0.52	-1.81	-3.5	-4.25	-0.64
Legal Settlements	-	-	-	-	-4.43	-
Pretax Income	17.26	17.54	16.21	13.46	12.86	2.24
Income Tax Expense	0.08	0.1	0.08	0.07	0.13	-
Earnings From Continuing Operations	17.18	17.44	16.13	13.39	12.73	2.24
Minority Interest in Earnings	-2.1	-1.85	-1.71	-0.91	-0.19	-1.23
Net Income	15.08	15.59	14.42	12.48	12.54	1.01
Net Income to Common	15.08	15.59	14.42	12.48	12.54	1.01
Net Income Growth	-16.32%	8.11%	15.58%	-0.46%	1147.02%	-93.11%
Shares Outstanding (Basic)	1,769	1,779	1,775	1,811	1,824	1,878
Shares Outstanding (Diluted)	1,769	1,779	1,775	1,811	1,824	1,878
Shares Change (YoY)	-2.88%	0.25%	-2.01%	-0.67%	-2.89%	-1.16%
EPS (Basic)	0.01	0.01	0.01	0.01	0.01	0.00
EPS (Diluted)	0.01	0.01	0.01	0.01	0.01	0.00
EPS Growth	-13.84%	7.85%	17.96%	0.22%	1184.86%	-93.03%
Free Cash Flow	18.8	19.55	15.44	18.58	27.9	11.54
Free Cash Flow Per Share	0.01	0.01	0.01	0.01	0.01	0.01
Dividend Per Share	0.003	0.003	0.004	0.003	0.005	0.003
Dividend Growth	-25.00%	-25.00%	37.93%	-40.82%	75.00%	-40.43%
Gross Margin	66.23%	68.10%	72.17%	73.33%	80.24%	64.08%
Operating Margin	58.03%	58.75%	61.53%	65.45%	73.47%	46.73%
Profit Margin	49.33%	49.80%	47.13%	42.12%	28.98%	5.05%
Free Cash Flow Margin	61.49%	62.41%	50.46%	62.72%	64.51%	57.98%
EBITDA	18.94	19.62	20.04	20.58	32.84	11.07
EBITDA Margin	61.95%	62.66%	65.46%	69.45%	75.92%	55.60%
D&A For EBITDA	1.2	1.22	1.2	1.18	1.06	1.76
EBIT	17.74	18.4	18.83	19.39	31.78	9.3
EBIT Margin	58.03%	58.75%	61.53%	65.45%	73.47%	46.73%
Effective Tax Rate	0.45%	0.57%	0.50%	0.54%	1.01%	-
Revenue as Reported	31.32	31.32	30.6	29.63	43.25	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.